Efficacy of a Single Autologous Stromal Vascular Fraction Injection for Moderate-to-Severe Knee Osteoarthritis: Insights from a Multicenter Randomized Controlled Trial

A single intra-articular injection of autologous adipose-derived stromal vascular fraction (SVF) cells significantly improves pain and function in moderate-to-severe knee osteoarthritis (OA) at 12 months compared to placebo.
The multicenter randomized placebo-controlled trial enrolled 114 patients meeting stringent radiographic and MRI criteria, assessing a 25 million SVF cell dose administered during the same clinical encounter.
The responder rate was 51.8% in the SVF group versus 29% in placebo, with no serious device-related adverse events reported, highlighting a favorable safety profile.

Specialty calculators

For clinical reference; use professional judgment.